China
Africa
Explore chapters and articles related to this topic
Special Considerations for Men's Health
Published in Gia Merlo, Kathy Berra, Lifestyle Nursing, 2023
Yohimbine was identified to improve erectile response as measured by penile rigidity and sexual function. The dosage of yohimbine was 36 mg daily. The adverse effects were agitation, anxiety, headache, a mild increase in blood pressure, increased urinary output, and gastrointestinal upset (Ernst & Pittler, 1998).
Drug Therapy for Obesity
Published in Ruth Chambers, Paula Stather, Tackling Obesity and Overweight Matters in Health and Social Care, 2022
Other potentially dangerous diet supplements can be bought online that might cause harm. Even if it is indicated that they should be bought directly from a pharmacist in the UK because of their medicinal properties, they can be readily purchased online from eBay, Wish.com and AliExpress, according to a recent Which? investigation.11 The investigators found that pills and powders containing yohimbine or synephrine were being promoted for weight loss that are extracted from herbs (from the bark of a tree and from bitter orange extract, retrospectively) and can inadvertently affect someone’s heart rate or blood pressure; these were easily bought from these online marketplaces.
The twentieth century
Published in Michael J. O’Dowd, The History of Medications for Women, 2020
This drug was touted as a cure for erectile dysfunction for many years. Reid and colleagues (1987) found that yohimbine had a modest effect on psychogenic impotence but no effect on organic erectile dysfunction. Pittler and Ernst (1998) carried out a metaanalysis on all the double-blind randomized placebo controlled trials of yohimbine for erectile dysfunction and claimed that yohimbine was an effective noninvasive option for initial drug treatment.
A literature perspective on the pharmacological applications of yohimbine
Published in Annals of Medicine, 2022
Nasimudeen R. Jabir, Chelapram K. Firoz, Torki A. Zughaibi, Mohammed Abdullah Alsaadi, Adel M. Abuzenadah, Ahmed Ibrahim Al-Asmari, Ahdab Alsaieedi, Bakrudeen Ali Ahmed, Arun Kumar Ramu, Shams Tabrez
Yohimbine is a prototypical α2-receptor antagonist used widely as a therapeutic agent against erectile dysfunction for many years. It interacts with other behaviourally relevant monoaminergic receptors, viz. α1, 5HT-1A, 5HT-1B, 1-D, D3, and D2. However, the exact mechanism of yohimbine action is unclear. Interestingly, yohimbine compounds meet fundamental drug-like criteria with DPQ and quantitative estimates of drug-likeness. Yohimbine’s inhibitory activity on the α2-adrenergic receptor is beneficial in various disease conditions such as erectile dysfunction, myocardial dysfunction, inflammatory disorders, and cancer. However, few studies reported toxicological concerns after yohimbine treatment for erectile dysfunctions, albeit at comparatively higher doses. The potential clinical applicability of yohimbine can be assessed by investigating the relative variables and genetic factors using preclinical models followed by clinical studies. Well-designed randomized clinical trials are recommended to evaluate the efficacy and safety of yohimbine as a human pharmaceutical agent. The extraction or neo-synthesis of yohimbine or its analogs with better bioavailability and limited toxicity is also a possible prospect. Some studies also highlighted a synergetic therapeutic effect of yohimbine with other relevant compounds. Therefore, the possibility of using yohimbine as an adjunct therapy for associated clinical conditions should be tested. Perhaps, nanotechnology can enhance the effectiveness and bioavailability of yohimbine in diseased cells by preventing the disruption of normal physiological activities of non-diseased cells and organs. Despite some observed adverse effects, yohimbine use should be reconsidered for its associated benefits and clinical value.